pSivida CEO to Present at 15th Annual BioCEO & Investor Conference February 12

  pSivida CEO to Present at 15th Annual BioCEO & Investor Conference February

Business Wire

WATERTOWN, Mass. -- February 4, 2013

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), an emerging specialty pharmaceutical
company and leader in developing sustained release, drug delivery products for
treatment of back-of-the-eye diseases, today announced that its President and
CEO, Dr. Paul Ashton, will present at the 15^th Annual BioCEO & Investor
Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and
Tuesday, February 11 and 12. Dr. Ashton will make his presentation on Tuesday,
February 12 at 1 p.m. EST. A webcast of the presentation will be available at: or at the
company’s website: There will be a webcast replay available
one hour after the conclusion of Dr. Ashton’s presentation that day and it
will be available until May 12, 2013.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drugs designed to be released at a controlled and steady rate for
months or years. pSivida is currently focused on treatment of chronic diseases
of the back of the eye utilizing its core technology systems, Durasert™ and
BioSilicon™. Two FDA-approved products, Vitrasert™ and Retisert™ are licensed
to Bausch & Lomb. The company has licensed ILUVIEN® for DME to Alimera
Sciences and that product has received marketing authorization in Austria,
France, Germany, Portugal, Spain and the UK. pSivida has clinical trials
ongoing for the treatment of posterior uveitis and glaucoma and hypertension.
Other technologies under development by pSivida include protein and antibody
delivery systems in early clinical stages.

1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: Alimera's ability to finance,
achieve additional marketing approvals, successfully commercialize and achieve
market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME
in the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's
resubmission of its NDA for ILUVIEN for DME and its ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; financing and success of Phase III
posterior uveitis trials including efficacy, side effects and risk/benefit
profile of the posterior uveitis micro-insert; initiation, financing and
success of Latanoprost Product Phase II trials and exercise by Pfizer of its
option; development of products using Tethadur and BioSilicon; initiation and
completion of clinical trials and obtaining regulatory approval of product
candidates; adverse side effects; ability to attain profitability; ability to
obtain additional capital; further impairment of intangible assets;
fluctuations in operating results; decline in royalty revenues; ability to,
and to find partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of products;
market acceptance; protection of intellectual property and avoiding
intellectual property infringement; retention of key personnel; product
liability; consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs of
international business operations; credit and financial market conditions;
legislative or regulatory changes; volatility of stock price; possible
dilution; possible influence by Pfizer; absence of dividends; and other
factors described in our filings with the SEC. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Our forward-looking statements speak only as of the dates on which
they are made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements will
not be realized.


Beverly Jedynak, President, Martin E. Janis & Company, Inc.
773-350-5793 (cell)
Brian Leedman, Vice President, Investor Relations, pSivida Corp.
+61 (0) 41 228 1780
Press spacebar to pause and continue. Press esc to stop.